News

Filter

Positive Ph III results for Relypsa’s patiromer FOS for hyperkalemia

22-11-2014

US biotech firm Relypsa announced that positive results from the pivotal Phase III program of the company's…

BiotechnologyNephrology and HepatologypatiromerRelypsaRenagelRenvelaResearchSanofiZS PharmaZS-9

Keryx' shares fall as FDA approves kidney drug, but with warnings

Keryx' shares fall as FDA approves kidney drug, but with warnings

07-09-2014

US drugmaker Keryx Biopharmaceuticals has received approval from the US Food and Drug Administration…

ferric citrateKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenvelaSanofiUSAZerenex

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Scottish Medicines Consortium approves MabThera for vasculitis, Lyxumia for diabetes and Targaxan for liver disease

10-09-2013

Drug regulator the Scottish Medicines Consortium (SMC) has today approved the National Health Service…

DiabetesEuropeHealthcareLyxumiaMabTheraNephrology and HepatologyNorginePharmaceuticalRocheSanofiTargaxan

Keryx Biopharma rockets on new Zerenex data and plans to file for approval

29-01-2013

USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

COMPANY SPOTLIGHT

Menarini

Back to top